1. Home
  2. BTDR vs TRVI Comparison

BTDR vs TRVI Comparison

Compare BTDR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bitdeer Technologies Group

BTDR

Bitdeer Technologies Group

N/A

Current Price

$5.67

Market Cap

1.6B

Sector

Technology

ML Signal

N/A

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

N/A

Current Price

$13.75

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTDR
TRVI
Founded
2021
2011
Country
Singapore
United States
Employees
N/A
34
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
BTDR
TRVI
Price
$5.67
$13.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
11
Target Price
$20.92
★ $28.18
AVG Volume (30 Days)
★ 10.1M
1.6M
Earning Date
11-10-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.91
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$54.56
N/A
Revenue Next Year
$70.16
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.03
$9.82
52 Week High
$20.72
$20.22

Technical Indicators

Market Signals
Indicator
BTDR
TRVI
Relative Strength Index (RSI) 36.09 48.85
Support Level $5.03 $13.00
Resistance Level $13.15 $14.75
Average True Range (ATR) 0.73 0.92
MACD 0.05 0.13
Stochastic Oscillator 19.28 39.87

Price Performance

Historical Comparison
BTDR
TRVI

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: